title: Analysis of vaccine-induced T cells in humans with cancer.
abstract: Over the past several years, progress in the field of tumor immunology has lead to advances in active immunotherapy and vaccination as a means ofeliciting tumor-specific immune responses to mediate tumor regression and clearance. Developing vaccines targeted against cancer became an important focus as a therapy following the success of viral vaccines in preventing infection and disease. In humans with cancer, similar to viral infections, the host immune system is capable of recognizing antigens expressed on tumor cells. This similarity allows the immunological framework of the viral vaccine to be adapted to the cancer setting in hopes of enhancing human T-cell reactivity against tumor. It is generally believed that a requirement for tumor destruction to occur is the induction of sufficient levels of immune cells with high avidity for recognition of tumor antigens. Moreover, the cells must be targeted to the tumor site and be capable of infiltrating tumor stroma.2 Several tumor-associated antigens (TAA) have been identified in the melanoma model which has allowed for immunization trials to evaluate therapeutic potential of tumor-specific T-cell induction. Some clinical trials reported limited success ofT-cell mediated tumor rejection, reportingpartial or complete regression in 10 to 30% of patients. Although tumor regression was not observed following active immunization in vivo, ex vivo assays evaluating TAA-specific T cells demonstrated tumor recognition and subsequent T-cell activation suggesting that tumor-specific T-cell induction indeed occurs but alone is not adequate to induce tumor regression. Recently, the usefulness and success of active-specific immunization (ASI) against TAAs as a means ofeliciting a tumor-specific immune response leading to tumor regression and clearance has been a topic of debate and discussion.
authors.affiliation: Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
authors.forename: Stefanie L
authors.initials: SL
authors.lastname: Slezak
authors.forename: Andrea
authors.initials: A
authors.lastname: Worschech
authors.forename: Ena
authors.initials: E
authors.lastname: Wang
authors.forename: David F
authors.initials: DF
authors.lastname: Stroncek
authors.forename: Francesco M
authors.initials: FM
authors.lastname: Marincola
mesh_terms: D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D016233:Immunotherapy, Active; D008213:Lymphocyte Activation / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology / Q000517:prevention & control; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines
references.citation: Blood. 1995 Aug 15;86(4):1408-19
references.pmid: 7632949
references.citation: J Immunother. 2002 Mar-Apr;25(2):97-138
references.pmid: 12074049
references.citation: Nature. 2000 Aug 3;406(6795):536-40
references.pmid: 10952317
references.citation: J Transl Med. 2007 Mar 28;5:17
references.pmid: 17391521
references.citation: Genome Biol. 2007;8(1):R8
references.pmid: 17222352
references.citation: J Immunol Methods. 1998 Mar 1;212(1):89-98
references.pmid: 9671156
references.citation: Cancer Res. 2004 Oct 15;64(20):7279-87
references.pmid: 15492247
references.citation: Adv Immunol. 2000;74:181-273
references.pmid: 10605607
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: Int J Cancer. 2003 Jun 10;105(2):210-6
references.pmid: 12673681
references.citation: Nat Med. 2004 Dec;10(12):1278-9; author reply 1279-80
references.pmid: 15580242
references.citation: J Transl Med. 2006 Nov 27;4:50
references.pmid: 17129373
references.citation: Cells Tissues Organs. 2004;177(3):124-31
references.pmid: 15388986
references.citation: Nat Immunol. 2002 Nov;3(11):999-1005
references.pmid: 12407407
references.citation: Prog Exp Tumor Res. 1970;13:1-27
references.pmid: 4921480
references.citation: Science. 2002 Oct 25;298(5594):850-4
references.pmid: 12242449
references.citation: J Immunol. 2000 Aug 15;165(4):2287-96
references.pmid: 10925318
references.citation: Science. 1996 Oct 4;274(5284):94-6
references.pmid: 8810254
references.citation: Urology. 1989 Feb;33(2):141-4
references.pmid: 2916288
references.citation: J Immunol. 2001 May 1;166(9):5817-25
references.pmid: 11313426
references.citation: Nat Med. 2004 Sep;10(9):909-15
references.pmid: 15340416
references.citation: N Engl J Med. 2003 Jul 10;349(2):125-38
references.pmid: 12853585
references.citation: J Transl Med. 2004 Oct 15;2(1):34
references.pmid: 15488140
references.citation: Nat Immunol. 2002 Nov;3(11):991-8
references.pmid: 12407406
references.citation: J Immunother. 2007 Jul-Aug;30(5):533-43
references.pmid: 17589294
references.citation: J Urol. 2003 Jul;170(1):178-9
references.pmid: 12796677
references.citation: Semin Cancer Biol. 2003 Dec;13(6):473-80
references.pmid: 15001166
references.citation: Lancet Oncol. 2004 Nov;5(11):681-9
references.pmid: 15522656
references.citation: J Immunol. 1999 Dec 15;163(12):6867-75
references.pmid: 10586088
references.citation: Nature. 2001 Apr 26;410(6832):1107-11
references.pmid: 11323675
references.citation: Cell. 2002 Dec 13;111(6):837-51
references.pmid: 12526810
references.citation: Semin Cancer Biol. 2003 Dec;13(6):461-72
references.pmid: 15001165
references.citation: Genome Biol. 2002 Jun 25;3(7):RESEARCH0035
references.pmid: 12184809
references.citation: J Immunother Emphasis Tumor Immunol. 1996 Jul;19(4):266-77
references.pmid: 8877721
references.citation: Clin Cancer Res. 2007 Jul 1;13(13):3776-82
references.pmid: 17606707
references.citation: J Immunol. 2002 Jan 1;168(1):338-47
references.pmid: 11751979
references.citation: Blood. 2004 Oct 1;104(7):1970-8
references.pmid: 15187028
references.citation: Immunity. 2004 Aug;21(2):137-48
references.pmid: 15308095
references.citation: J Immunol. 1999 Dec 1;163(11):6292-300
references.pmid: 10570323
references.citation: J Immunol. 2008 Feb 1;180(3):1362-72
references.pmid: 18209030
references.citation: Eur J Cancer. 2006 Jul;42(10):1322-30
references.pmid: 16737813
references.citation: Lancet. 2008 Mar 1;371(9614):771-83
references.pmid: 18275997
references.citation: Cancer Immunol Immunother. 2007 Jul;56(7):1047-63
references.pmid: 17124584
references.citation: J Immunother. 2008 Jan;31(1):101-12
references.pmid: 18157017
references.citation: Cancer Res. 2002 Jul 1;62(13):3581-6
references.pmid: 12097256
references.citation: J Transl Med. 2008 Apr 15;6:17
references.pmid: 18412971
references.citation: J Natl Cancer Inst. 2000 Aug 16;92(16):1336-44
references.pmid: 10944556
references.citation: Trends Immunol. 2003 Jun;24(6):335-42
references.pmid: 12810110
references.citation: Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2346s-2352s
references.pmid: 16609057
references.citation: Expert Opin Biol Ther. 2008 Mar;8(3):337-49
references.pmid: 18294104
references.citation: Immunity. 2008 Jul 18;29(1):9-11
references.pmid: 18631452
references.citation: Curr Opin Immunol. 2005 Aug;17(4):423-7
references.pmid: 15950448
references.citation: J Natl Cancer Inst. 2002 Jun 5;94(11):805-18
references.pmid: 12048268
references.citation: Annu Rev Immunol. 2004;22:329-60
references.pmid: 15032581
references.citation: PLoS Med. 2005 Oct;2(10):e265
references.pmid: 16162034
references.citation: J Transl Med. 2004 Jun 2;2(1):17
references.pmid: 15175100
references.citation: Eur J Cancer. 2006 May;42(8):1031-9
references.pmid: 16616487
references.citation: Int J Cancer. 1998 Dec 9;78(6):699-706
references.pmid: 9833762
references.citation: Clin Cancer Res. 2005 Jan 1;11(1):113-22
references.pmid: 15671535
references.citation: Am J Clin Oncol. 1997 Aug;20(4):416-8
references.pmid: 9256902
references.citation: Trends Immunol. 2008 Jun;29(6):256-62
references.pmid: 18457994
references.citation: J Transl Med. 2005 Apr 14;3(1):16
references.pmid: 15831096
references.citation: J Exp Med. 1997 Aug 29;186(5):645-53
references.pmid: 9271580